|
|
|
| home > white papers > Soothing the Logistical Headache of Clinical Trials - Equilibrium Travel Management |
|
|
 WHITE PAPERS |
|
Equilibrium Travel Management
|
|
Soothing the Logistical Headache of Clinical Trials
|
|
As many as 30 per cent of subjects on phase three clinical studies drop out. Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial. It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase
AirBridgeCargo expands its passive pharma solutions in partnership with
SkyCell as it achieves the two-fold volume increase AirBridgeCargo
Airlines (ABC), one of the leaders in transportation of pharmaceutical
products by air, and Zurich-based cold-chain ULD manufacturer SkyCell
have sealed their partnership for the lease of all types of SkyCell
containers to meet the demand for evolving volumes of passive
pharmaceutical shipments, which reached around 3,500 tonnes for 1Q 2019
YOY and demonstrated a two-fold increase.
More info >> |
|
 |
White Papers |
 |
|
Autoinjector testing made safe efficient and flexible
ZwickRoell
The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >> |
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
|
|
